CF
OKUR

Cantor Fitzgerald’s OnKure Therapeutics OKUR Stock Holding History

Cantor Fitzgerald’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$414K Sell
99,900
-345,178
-78% -$1.07M 0.01% 227
2025
Q4 		$1.29M Sell
445,078
-46,785
-10% -$140K 0.02% 149
2025
Q3 		$1.35M Sell
491,863
-177,676
-27% -$440K 0.01% 189
2025
Q2 		$1.6M Buy
669,539
+538,839
+412% +$1.41M 0.03% 123
2025
Q1 		$562K Buy
130,700
+95,000
+266% +$534K 0.01% 144
2024
Q4 		$294K Buy
+35,700
New +$540K 0.01% 150

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cantor Fitzgerald's OKUR Position: Q1 2026 in Review

Cantor Fitzgerald reduced its OnKure Therapeutics (OKUR) stake by 78% in Q1 2026, selling an estimated $1.07M and leaving 99,900 shares worth $414K. The position accounts for 0.01% of the portfolio, ranked #227.

Cantor Fitzgerald first reported a position in OKUR in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.6M in Q2 2025. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Cantor Fitzgerald held 99,900 shares of OnKure Therapeutics worth $414K as of Q1 2026.
  • Cantor Fitzgerald sold 345,178 OnKure Therapeutics shares in Q1 2026, an estimated $1.07M.
  • OnKure Therapeutics made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #227 holding.
  • Cantor Fitzgerald first reported a position in OnKure Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Cantor Fitzgerald's OnKure Therapeutics position peaked at $1.6M in Q2 2025.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.